MS and Demyelinating Disorders

Fred D. Lublin, MD discusses the diagnosis of multiple sclerosis and the 2017 revisions of the McDonald criteria.  

Robert Zivadinov, MD, PhD, director, Buffalo Neuroimaging Analysis Center, spoke to the findings of a post-hoc analysis of atrophied T2-lesion volume as a biomarker in patients with progressive MS.

Here's what is coming soon to NeurologyLive.

We kindly ask you to share 5 minutes of your time with us in order to help us better understand how you use social media and how we can better serve you across different platforms.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending June 25, 2021.

A significantly higher percentage of patients treated with ublituximab compared to those on teriflunomide achieved no evidence of disease activity status.

Alise Carlson, MD, resident of Cleveland Clinic, details the factors and long-term effects misdiagnosing a patient with multiple sclerosis can have on their quality of life.

At baseline, a negative correlation was noted between average cognition and VAN importance in both groups, indicating that lower VAN importance is related to a higher average cognition.

Advice to community physicians and neurologists who play a role in caring for patients with multiple sclerosis in community practices on optimizing therapy with high-efficacy and newer treatment options.

Here's what is coming soon to NeurologyLive.

The head of global research and executive vice president of Atara Biotherapeutics discussed the upcoming study evaluating ATA188.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending June 18, 2021.

Join Ahmed Obeidat, MD, PhD; Anne Cross, MD; and Gloria von Geldern, MD, for the third program in this series, where they offer insight from neurology specialists on applying lessons learned from the COVID-19 pandemic into clinical practice when managing patients with multiple sclerosis.

The nurse practitioner at the Woodruff School of Nursing at Emory University detailed why a cultural shift is needed to incorporate APCs into the neurology space and thus improve multidisciplinary care.

All agree that having a simple, standardized serum biomarker to measure disease activity would offer the greatest utility in treating a medical condition such as MS, which now has a variety of graded therapies available.

These consensus guidelines are significant not only for their key updates to clinical practice but for their representation of a more unified, global approach to diagnosing and monitoring patients with multiple sclerosis.

Gaps in care that neurologists experience when treating patients with relapsing-remitting multiple sclerosis and considerations for recommending lifestyle modifications to help manage symptoms.

Exciting strategies and biomarkers being investigated to improve the evaluation and treatment of patients with relapsing-remitting multiple sclerosis.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending June 11, 2021.

Key opinion leaders in neurology, Lawrence Steinman, MD and Enrique Alvarez, MD, PhD, reflect on future developments in the management of multiple sclerosis and share key advice for community physicians.

Thought leaders in neurology consider the role of BTK inhibitors such as evobrutinib and review the potential impact on patients with progressive multiple sclerosis.

Drs Patricia K. Coyle and Robert Fox comment on approaching multiple sclerosis relapses as early as possible with high-efficacy therapy.

Factors that may warrant a switch in therapy to treat relapsing-remitting multiple sclerosis.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending June 4, 2021.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Barry Hendin, MD.

The head of global research and executive vice president of Atara Biotherapeutics discussed improvements seen in patients treated with the investigational therapy.

Robert Zivadinov, MD, PhD, professor of neurology and director of the Buffalo Neuroimaging Analysis Center, discussed the post-hoc analysis of the ORATORIO trial he and colleagues conducted.

The neurologist from Banner Health and chief medical officer of the MS Association of America detailed the significant changes to the state of multiple sclerosis care over the past 3 decades.